IONS — Ionis Pharmaceuticals Balance Sheet
0.000.00%
- $12.32bn
- $11.31bn
- $705.14m
- 76
- 13
- 100
- 69
Annual balance sheet for Ionis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-Q | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,892 | 2,115 | 1,987 | 2,331 | 2,298 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 76.2 | 61.9 | 25.5 | 97.8 | 92.2 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,131 | 2,345 | 2,203 | 2,642 | 2,620 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 181 | 196 | 256 | 243 | 256 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,390 | 2,612 | 2,534 | 2,990 | 3,004 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 599 | 241 | 312 | 448 | 309 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,646 | 1,840 | 1,961 | 2,603 | 2,415 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 743 | 772 | 573 | 387 | 588 |
| Total Liabilities & Shareholders' Equity | 2,390 | 2,612 | 2,534 | 2,990 | 3,004 |
| Total Common Shares Outstanding |